Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.93 USD
Change Today -0.045 / -0.50%
Volume 2.6M
ARIA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (ARIA) Snapshot

Open
$9.01
Previous Close
$8.97
Day High
$9.05
Day Low
$8.89
52 Week High
04/24/15 - $9.89
52 Week Low
10/13/14 - $4.90
Market Cap
1.7B
Average Volume 10 Days
3.3M
EPS TTM
$-0.88
Shares Outstanding
188.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARIAD PHARMACEUTICALS INC (ARIA)

ariad pharmaceuticals inc (ARIA) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (ARIA) Details

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

379 Employees
Last Reported Date: 03/2/15
Founded in 1991

ariad pharmaceuticals inc (ARIA) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $676.0K
President of Research & Development and Chief...
Total Annual Compensation: $858.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $683.4K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $647.0K
Compensation as of Fiscal Year 2014.

ariad pharmaceuticals inc (ARIA) Key Developments

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial

ARIAD Pharmaceuticals Inc. announced long-term follow-up data from the Phase 1 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). With a median follow-up of over four years (53.1 months), Iclusig continues to demonstrate anti-leukemic activity in chronic-phase (CP) CML patients with limited treatment options (n=43). Overall, 72% of CP-CML patients achieved a major cytogenetic response (MCyR) on trial, 65% a complete cytogenetic response (CCyR) and 56% a major molecular response (MMR). Long-term safety data on ponatinib indicate that benefit-risk evaluations should guide decisions to initiate and maintain therapy, particularly in patients who may be at increased risk for arterial occlusive events. The Phase 1 dose-escalation study of ponatinib (dose range, 2 to 60 mg once daily) enrolled 81 patients with resistant or refractory hematologic cancers, including 43 patients with CP-CML. 60% of CP-CML patients in this study had failed at least three prior tyrosine kinase inhibitors (TKI), and 98% received at least two prior TKIs. Twenty-two CP-CML patients (51%) remain on study. Data presented at ASCO focus on CP-CML patients and represent follow-up through February 2, 2015. Median follow-up for CP-CML patients is over 4 years (53.1 months) with a maximum follow-up of six years (69.9 months). Of 22 ongoing CP-CML patients, 14 are receiving a dose of 15 mg/day ponatinib or less, 5 on 30 mg/day, and 3 on 45 mg/day; the mean current dose is 22.5 mg/day. The median dose intensity for these patients during the course of the study was 33.7 mg/day. Anti-leukemic activity continues to be observed with ponatinib treatment: 72% of CP-CML patients achieved MCyR, 65% CCyR and 56% MMR. Of note, 77% (17/22) of ongoing CP-CML patients are in deep molecular response of MMR or better. The median times to MCyR, CCyR and MMR were 2.8, 5.5 and 7.4 months, respectively. By Kaplan-Meier estimate, the probability of CP-CML patients maintaining MCyR at 4 years was 71%. Ten of the 15 CP-CML patients (67%) who started ponatinib at a dose of 30 mg or less achieved MCyR. Of the 12 CP-CML patients with the T315I mutation enrolled in the trial, 1 discontinued; 10 of the 11 CP-CML patients with the T315I mutation who remained on study achieved MCyR, with 8 of 10 in continuous MCyR. The most common treatment-emergent adverse events (= 50%) occurring in CP-CML patients were rash (65%), fatigue (63%), abdominal pain (58%), headache (58%), arthralgia (53%), and constipation (51%). The most common serious treatment-emergent adverse events were abdominal pain, atrial fibrillation, myocardial infarction, and pancreatitis (n=4 each). Thirty% (n=13) of CP-CML patients experienced a serious arterial occlusive event (AOE); 40% (n=17) of CP-CML patients experienced an AOE of any severity. Two patients experienced a venous thromboembolic event (VTEs); no serious VTEs were observed. No patient death was attributed to an AOE or VTE. No new AOEs have been reported since study data were last reported in December 2014 (data as of September 26, 2014).

Ariad Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Ariad Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $23,991,000 against $11,782,000 a year ago. Net loss was $52,676,000 or $0.28 basic and diluted per share against $49,822,000 or $0.27 basic and diluted per share a year ago. Net cash used in operating activities was $50,194,000 against $52,409,000 a year ago.

Ariad Pharmaceuticals Inc. Announces Management Changes

ARIAD Pharmaceuticals Inc. announced that founder, Harvey J. Berger, M.D., has informed the Board of Directors of his decision to retire as chairman and chief executive officer upon appointment of his successor or December 31, 2015, whichever is earlier. In addition, under the terms of the settlement, ARIAD’s Board has appointed Anna Protopapas by filling an existing open director seat on the Board. Sarissa will withdraw its proposed slate of director nominees, which included Ms. Protopapas, for election at the 2015 annual meeting and has agreed to vote all of its shares in favor of the Board’s nominees. Ms. Protopapas is Chief Executive Officer of Mersana Therapeutics. She previously served as a member of the Executive Committee of Takeda Pharmaceutical Company Limited and held various senior management positions, including President of Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARIA:US $8.93 USD -0.045

ARIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.23 USD +0.04
Array BioPharma Inc $7.72 USD -0.015
Evotec AG €3.70 EUR -0.046
Insys Therapeutics Inc $61.81 USD +2.21
Pfizer Ltd/India 2,133 INR -34.85
View Industry Companies
 

Industry Analysis

ARIA

Industry Average

Valuation ARIA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.3x
Price/Book 44.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit www.ariad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.